Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement Journal Article
| Authors: | Ryan, C. E.; Zon, R. L.; Redd, R.; Fisher, D. C.; Shouval, R.; Kumar, A.; Crombie, J. L.; Sadrzadeh, H.; Kim, A. I.; Nayak, L.; Chukwueke, U. N.; Jacobson, C. A.; Frigault, M. J.; Palomba, M. L.; Armand, P.; Epstein-Peterson, Z.; Merryman, R. W. |
| Article Title: | Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement |
| Abstract: | Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited. We identified 10 patients with MCL and SCNS involvement treated with anti-CD19 CAR T-cell therapy at three US academic centres. Frequent objective responses were observed in the CNS (86%) and systemically (90%), and the 1-year progression-free survival was 47%. Seven patients developed immune-effector-cell-associated-neurotoxicity-syndrome (n = 2 Grade 1, n = 5 Grade 3). Our results suggest that anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted. © 2023 British Society for Haematology and John Wiley & Sons Ltd. |
| Keywords: | adult; clinical article; treatment outcome; treatment response; aged; neurotoxicity; t lymphocyte; t-lymphocytes; cancer immunotherapy; progression free survival; mantle cell lymphoma; retrospective study; central nervous system; feasibility study; receptors, antigen, t-cell; patient safety; chimeric antigen receptor; effector cell; clinical effectiveness; biological therapy; adoptive immunotherapy; immunotherapy, adoptive; cd19 antigen; lymphocyte antigen receptor; antigens, cd19; lymphoma, mantle-cell; non-hodgkin lymphoma; cns; clinical outcome; procedures; neurotoxicity syndromes; cancer prognosis; cd19 antibody; humans; human; male; female; article; cell- and tissue-based therapy; central nervous system cancer; chimeric antigen receptor t-cell immunotherapy; immune effector cell associated neurotoxicity syndrome; cellular therapies; receptors, chimeric antigen; brexucabtagene autoleucel; toxicity and intoxication; secondary central nervous system involvement |
| Journal Title: | British Journal of Haematology |
| Volume: | 203 |
| Issue: | 5 |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2023-12-01 |
| Start Page: | 774 |
| End Page: | 780 |
| Language: | English |
| DOI: | 10.1111/bjh.19037 |
| PUBMED: | 37584155 |
| PROVIDER: | scopus |
| PMCID: | PMC10843463 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work